No recruitment

The tacrolimus-Everolimus association is used as an immunospressive treatment after a kidney transplant. It combined immunosupressive properties of both products and reduce the nephrotoxicity of tacrolimus by lowering the dosage.

The commercialisation of a new extended release Tacrolimus pharmaceutical form and the lack of information justify a modality of use and tolerence evaluation of this new association, commonly used.

Inclusion Criteria:

• Patients over 18 years old
• Patients informed and giving his agreement to the use of every collected data
• Patients with kidney transplantation for at least one year and being treated with the immunosppressive assiociation of Tacrolimus (Prograf ®)-Everolimus
• Patients whose investigators decides to switch from Prograf ® to an Envarsus ®-Everolimus association

Exclusion Criteria:

• Other transplantation
• Drug or alcohol abuse
• Patients unable to understand the purpose or modalities of this study, unable to give his agreement or unable to stick to the protocol
• Patients on an interventionnal protocol when included

Patients over 18 years old with kidney transplantation for at least one year.